MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Leukemic Stem Cells

Search medical newsFind research, conditions and clinical updates
  • Home
  • Leukemic Stem Cells
Targeting Leukemic Stem Cells in AML: Overcoming PI3K Inhibitor Resistance through Epigenetic Modulation
Posted inHematology-Oncology news Oncology

Targeting Leukemic Stem Cells in AML: Overcoming PI3K Inhibitor Resistance through Epigenetic Modulation

Posted by By MedXY 10/08/2026
This article explores novel therapeutic strategies in acute myeloid leukemia by combining PI3K inhibitors with EZH1/2 dual inhibitors to overcome epigenetic resistance mechanisms in leukemic stem cells, offering promising pathways to prevent relapse.
Read More
IDH3 as a Metabolic Checkpoint Modulating Venetoclax Resistance in AML Stem Cells
Posted inHematology-Oncology news

IDH3 as a Metabolic Checkpoint Modulating Venetoclax Resistance in AML Stem Cells

Posted by By MedXY 09/27/2026
This article elucidates how the TCA cycle enzyme IDH3 critically regulates metabolic fitness in AML stem cells, influencing venetoclax resistance and offering a novel target to improve therapeutic outcomes.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Immersive Virtual Reality Enhances Naming Therapy in Chronic Post-Stroke Aphasia: A Randomized Controlled Trial
  • Metagenomic Insights into Salivary Microbiome Shifts During Periodontal Disease Progression
  • Comparative Effectiveness of Responsive Management Versus Renal Dialysis in Elderly UK Patients with Kidney Failure and Frailty: Insights from the Prepare for Kidney Care Trial and Related Advances
  • A U.S. Islamic Fatwa Supporting Pasteurized Donor Human Milk: How Clinicians Can Use Faith Guidance to Improve Neonatal Equity
  • Rising Global Impact and Economic Burden of Musculoskeletal Disorders Among Working-Age Adults (1990–2023)
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top